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Sphingosine-1-phosphate receptor 1 (S1PR1) plays a crucial role in infectious diseases. Targeting S1PR1 provides protection
against pathogens, such as inﬂuenza viruses. This study is aimed at investigating S1PR1 in response to bacterial infection by
assessing S1PR1 expression in S. aureus-infected mice. A rodent local muscle bacterial infection model was developed by
injecting S. aureus to the lower hind limb of Balb/c mice. The changes of S1PR1 expression in response to bacterial infection
and blocking treatment were assessed using ex vivo biodistribution and in vivo positron emission tomography (PET) after
intravenous injection of an S1PR1-speciﬁc radiotracer [18F]TZ4877. The speciﬁcity of [18F]TZ4877 was assessed using S1PR1speciﬁc antagonist, NIBR-0213, and S1PR1-speciﬁc DsiRNA pretreated the animals. Immunohistochemical studies were
performed to conﬁrm the increase of S1PR1 expression in response to infection. Ex vivo biodistribution data showed that the
uptake of [18F]TZ4877 was increased 30.6%, 54.3%, 74.3%, and 115.3% in the liver, kidney, pancreas, and thymus of the
infected mice, respectively, compared to that in normal control mice, indicating that S1PR1 is involved in the early immune
response to bacterial infection. NIBR-0213 or S1PR1-speciﬁc DsiRNA pretreatment reduced the tissue uptake of [18F]TZ4877,
suggesting that uptake of [18F]TZ4877 is speciﬁc. Our PET/CT study data also conﬁrmed that infected mice have increased
[18F]TZ4877 uptake in several organs comparing to that in normal control mice. Particularly, compared to control mice, a 39%
increase of [18F]TZ4877 uptake was observed in the infected muscle of S. aureus mice, indicating that S1PR1 expression was
directly involved in the inﬂammatory response to infection. Overall, our study suggested that S1PR1 plays an important role in
the early immune response to bacterial infection. The uptake of [18F]TZ4877 is tightly correlated with the S1R1 expression in
response to S. aureus infection. PET with S1PR1-speciﬁc radiotracer [18F]TZ4877 could provide a noninvasive tool for
detecting the early S1PR1 immune response to infectious diseases.

1. Introduction
Staphylococcus aureus (S. aureus) is a commensal human
microbiota with approximately 30% of the human population which is colonized with S. aureus [1]. S. aureus often
causes skin and soft tissue infections but can also cause
pneumonia, bloodstream infections, endocarditis, and osteomyelitis [2–4]. To date, with the majority of studies focused
on virus infection, particularly inﬂuenza, only little is known

about the role of sphingosine-1-phosphate (S1P) and S1P
receptors (S1PRs) in response to bacterial infection. Igawa
and colleagues demonstrated that the expression of S1PR2
was elevated in S. aureus-treated human epidermal keratinocytes; they also showed that both S1PR1 and S1PR2
controlled the proinﬂammatory cytokine expression and
secretion during the S. aureus invasion [5].
S1P binds to speciﬁc G protein-coupled S1P receptors 15 and triggers the S1P/S1PR pathway which plays a
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regulatory role in many pathophysiological processes, including angiogenesis [6], neurodegeneration [7], and immune
response [8]. Intriguingly, it has been reported that S1P
signaling via S1PRs is related to various aspects of inﬂammatory cell function. Accumulated evidence suggests that the
S1P/S1PR pathway is impaired during infectious diseases.
Furthermore, the S1P/S1PR pathway also plays an important
role in infection-induced sepsis [9–11]. As a consequence, the
S1P/S1PR pathway has been widely accepted as a therapeutic
target in inﬂammatory and infection diseases [12]. Of note,
several multiple sclerosis (MS) disease-modifying therapies
targeting S1P/S1PRs are under investigation for treating
coronavirus disease-2019 (COVID-19) [13, 14].
Out of the ﬁve S1PRs, S1PR1 is the most abundant S1P
receptor and is widely studied in diﬀerent diseases. It is ubiquitously expressed among tissues and is heavily involved in
immune cell regulation. S1PR1 has been found to mediate
functions in most immune cells and therefore plays a curial
role in both innate and adaptive immune responses [15].
Previous studies suggest that S1PR1 is essential for lymphocyte recirculation by regulating lymphocyte egress from both
the thymus and peripheral lymphoid organs [16, 17]; activation of S1PR1 inhibits the migration of T lymphocytes into
diﬀerent lymphatics and results in retention of T lymphocytes in nonlymphoid peripheral tissues [18]. S1PR1 also
regulates the migration of B lymphocytes and osteoclasts
[19, 20]. It was reported that S1PR1 plays an important role
in the immune response to infectious diseases by regulating
recruitment and traﬃcking of innate immune cells, macrophage polarization [21], and dendritic cell functions [22].
In addition, S1PR1 is considered to play a critical role in
the development of sepsis [11]; for example, S1PR1-speciﬁc
agonist SEW2871 can successfully protect against renal
injury in a sepsis model [23]. Numerous studies show that
S1PR1 expression or activation is tightly correlated with
the inﬂammatory response to infectious diseases such as
Newcastle disease virus infection [24], inﬂuenza A virus
H1N1 [25], H9N2 infection [26], herpes simplex virus type
1 infection [27], Pseudomonas aeruginosa lung infection
[28], and human immunodeﬁciency viruses HIV-1 infection
[29]. It is also believed that host-directive therapy using
modulators of S1PR1 and other S1PRs may be an eﬀective
treatment against severe infectious diseases, such as severe
acute respiratory syndrome (SARS) and COVID-19 [30].
Despite the current understanding of S1PR1 in normal
lymphocyte traﬃcking, the precise mechanisms of S1PR1
activation in response to pathogen-derived pathological
infectious consequences remain not clear.
Our previous positron emission tomography (PET)
studies with S1PR1-speciﬁc tracer demonstrated an
increased expression of S1PR1 in rodent models of vascular
inﬂammation and neuroinﬂammation [31, 32]. To evaluate
the ability of S1PR1-speciﬁc tracer for the assessment of
other inﬂammatory diseases, as well as to further understand
the role of S1PR1 in response to pathogen infection, we performed ex vivo biodistribution, microPET, and immunohistochemistry staining studies to investigate S1PR1 expression
on S. aureus-infected mice using our recently reported
S1PR1-speciﬁc radiotracer [ [18]F]TZ4877 [33–35]. In our
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studies, we observed an increased uptake of [18F]TZ4877 in
several organs in response to the infection; a 39% increase
of [18F]TZ4877 uptake was also observed at the local hind
limb muscle infected site. Our results indicated that the
infection-induced increase of S1PR1 expression is tightly
correlated with pathogen-derived inﬂammation. Our ﬁndings are consistent with other studies that S1PR1 plays a
critical role in response to pathogen infection.

2. Materials and Methods
2.1. Animals. All animal experiments were conducted by
following the Guidelines for the Care and Use of Research
Animals under a research protocol approved by Washington
University Institutional Animal Care and Use Committee
(IACUC). Biodistribution and microPET/CT studies were
conducted in Preclinical Imaging Facility at Washington
University School of Medicine in St. Louis. For infection
model, mice were injected with bacteria or PBS under 2–
3% isoﬂurane in O2. For biodistribution study, mice were
euthanized by cervical dislocation under anesthesia with 2–
3% isoﬂurane in O2 and then, tissues of interest were
collected. For microPET/CT studies, mice were euthanized
by CO2 inhalation after use.
2.2. Radiosynthesis. S1PR1-speciﬁc radiotracer [18F]TZ4877
was used in this study in order to detect changes of S1PR1
in response to S. aureus infection. The synthesis and quality
control of [18F]TZ4877 were achieved as previously reported
(Figure 1(a)) [33]. For each batch, the synthesis of
[18F]TZ4877 was accomplished with a radiochemical purity
of >99%, chemical purity of >95%, and molar activity of
>48 GBq/μmol (decay corrected to the end of synthesis, EOB).
2.3. Bacterial Cell Culture. Staphylococcus aureus (ATCC
29213) was purchased from the American Type Culture Collection. The stock S. aureus was plated on LB agar plates
overnight; individual colony was picked from LB agar plate
and cultured in Trypticase Soy Broth at 37°C and 210 rpm
until approximately 10 × 108 /mL of bacterial concentration
was reached. The bacterial concentration was measured
using a DEN-1 densitometer (Grant Instruments, UK). S.
aureus was then centrifuged and resuspended in 25 μL of
PBS at a colony-forming unit (CFU) of 1 × 108 CFU of live
bacteria for high titer and 1 × 106 CFU of live bacteria for
low titer and used immediately.
2.4. S. aureus Infection through Local Inoculation. All experimental procedures involving animals were performed
according to guidelines established by the Animal Studies
Committee at Washington University in St. Louis. Sevenweek-old Balb/c mice (Charles River, Wilmington, MA)
were used in all studies. All animals were randomly assigned
to each study group. In order to evaluate the eﬀect of S.
aureus infection on S1PR1, a bacterial infection model was
created following the previously described procedure
[36–38]. Previous studies demonstrated that S1PR1 is significantly increased 24 hours after Newcastle disease virus
infection; in order to detect the change of S1PR1 expression
using PET imaging, a relatively high dose of S. aureus and
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Figure 1: MicroPET imaging of S1PR1 activity in S aureus-infected mice. (a) Radiosynthesis of S1PR1-speciﬁc radiotracer, [ F]TZ4877; (b)
representative sagittal microPET images of [18F]TZ4877 in mice. Comparing with sham mice, the tracer uptake was signiﬁcantly higher in
the infected mice, and the increased uptake of the tracer showed S aureus dose dependent; (c) the tracer uptake in the brain was quantiﬁed;
time-activity curves showed that the tracer uptake in infected mice was signiﬁcantly higher than mice without infections; (d) the average
tracer uptake in the brain from 30 to 50 min of the PET scan showed a dose-dependent manner. Data represent the mean ± SEM, n = 3
for each group.
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24-hour treatment were used for initial evaluation of the
response of S1PR1 to the bacterial infection. In fact, it has
been reported that 10 [7] to 10 [9] CFU S. aureus can cause
bacteria to elicit inﬂammatory responses within 24 hours
[39–41], and intravenous inoculation of 5 × 107 to 5 × 108
CFU S. aureus can cause the animal to develop septic shock
within 48 hours [42]. In our case, 1 × 108 CFU (high titer)
and 1 × 106 CFU (low titer) of live S. aureus were diluted
in 25 μL PBS and injected in the muscle of the lower hind
limb 24 hours prior to the study; 25 μL of sterilized PBS
was also injected to the contralateral limb as an internal control; in the meantime, a group of sham animals received the
same volume of sterile PBS. For blocking studies, either
S1PR1-speciﬁc ligand NIBR-0213 (Sigma-Aldrich, St. Louis,
MO) at a dose of 5 mg/kg or S1PR1-speciﬁc DsiRNA
(mm.Ri.S1pr1.13, Integrated DNA Technologies, Coralville,
IA) at a dose of 20 μg/kg was administered 12 hours prior
to injection of radiotracer, noticing that NIBR-0213 has a
long elimination half-life and prolonged duration of action

in rodent [43]. In addition, our initial pilot test demonstrated that NIBR-0213 can successfully block our radiotracer long time after treatment.
2.5. Ex Vivo Biodistribution Studies. To characterize the distribution and kinetics of [18F]TZ4877 in diﬀerent tissues
in normal mice, we performed an ex vivo biodistribution
study in normal Balb/c mice as previously described with
minor modiﬁcations [33]. In brief, approximately
2.2 MBq/100 μL of the radiotracer was administrated to
the mice intravenously via the tail vein. At 5, 30, or
60 min posttracer injection, animals were euthanized and
tissues of interest including the blood, lung, liver, spleen,
kidney, muscle, heart, brain, pancreas, thymus, and small
intestine were collected, weighed, and counted in a Beckman 8000 automated gamma counter (Beckman, Brea,
CA). The radiotracer uptake in each tissue was calculated
as background and decay-corrected percent injected dose
per gram (%ID/g).
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To determine the radiotracer uptake in diﬀerent tissues
in response to S. aureus infection, we then performed an
ex vivo biodistribution study in normal and S. aureusinfected Balb/c mice. After 24 hours of infection through
local inoculation, biodistribution study was performed as
described above, tissues of interest from sham and infected
mice were collected 30 min posttracer injection, and the
uptake in each tissue was calculated. To determine if the
increased uptake of [18F]TZ4877 was caused by endogenous
S1PR1 activation, the infected mice were pretreated with an
S1PR1-speciﬁc antagonist, NIBR-0213 [43], at 5 mg/kg and
12 hours prior to tracer injection. In addition, we used
S1PR1-speciﬁc DsiRNA at 20 μg/kg pretreatment in mice
12 hours prior to tracer injection to further conﬁrm that
[18F]TZ4877 is speciﬁc to S1PR1 in vivo, rather than other
S1P receptor subtypes. The infected mice received 1 × 106
CFU of live S. aureus that was diluted in 25 μL PBS and
injected into the muscle of the lower hind limb 24 hours
prior to the study.

data was reconstructed per time frame using an interactive
reconstruction algorithm and corrected for decay. The tissue
uptake of the radioactivity was measured from elliptical
ROIs, and percent injected dose per gram of tissue (%ID/g)
was calculated. To determine if the uptake of [18F]TZ4877
was correlated with the severity of the infection, microPET
studies were also performed in mice that were injected with
a high dose of live S. aureus (1 × 108 CFU of live S. aureus).

2.6. Immunohistochemistry. To conﬁrm the increased uptake
of [18F]TZ4877 in S. aureus-infected mice is caused by the
upregulation of S1PR1, immunohistochemistry staining
was performed in hind limb muscle from sham and S.
aureus-infected mice. 14-micron sections from fresh frozen
tissue were used. Sections were prewarmed to room temperature and ﬁxed with 4% paraformaldehyde in PBS for 15
minutes and then washed in PBS. Sections were then incubated in Antigen Retrieval Buﬀer (Abcam, Cambridge,
MA) for 20 minutes in boiling water bath and then blocked
with 5% horse serum for 2 hours at room temperature
followed by blocking with ReadyProbes Endogenous HRP
and AP Blocking Solution (ThermoFisher, Waltham, MA).
After washing in PBS, all sections were then incubated with
rabbit anti-S1PR1 (Alomone, Israel) antibody overnight at
4°C and then washed and incubated with ImmPRESS HRP
Horse anti-rabbit polymer for 1 hour at room temperature
and developed with ImmPACT DAB (Vector Laboratories,
Burlingame, CA).

3. Results

2.7. MicroPET/CT Studies. To conﬁrm the changes of S1PR1
expression in response to S. aureus inoculation, as well as to
evaluate the feasibility of our S1PR1-speciﬁc radiotracer in
detecting the infection-induced S1PR1 activation, microPET/CT studies of [18F]TZ4877 were performed in normal
controls and S. aureus-infected mice. For the microPET
studies, an Inveon MM PET/CT scanner (Siemens, Germany) was used; mice were anesthetized with 2% isoﬂurane
under gas anesthesia during the imaging data collection
period. Mice were secured using a custom-designed acrylic
restraining device. Following a transmission scan and a
computed tomography for anatomical registration, 6.87.6 MBq/mouse of [18F]TZ4877 was administrated via the
tail vein using a catheter for injection. A list-mod protocol
was used with 60-minute dynamic data acquisition with a
dynamic sequence of 1 × 3 s, 6 × 2 s, 9 × 5 s, 6 × 10 s, 4 × 30
s, 2 × 1 min, 2 × 2 min, and 10 × 5 min frames. PET image
data was processed and analyzed using Inveon Research
Workstation software IRW 4.2 (Siemens, Germany). The

2.8. Statistical Analysis. All data were analyzed with Prism
7.0 (GraphPad Software, San Diego, CA). Two-way
ANOVA and paired Student t-test were used for comparison of percent injected dose per gram of tissue from ROI
for PET study; two-way ANOVA with a relatively powerful
Fisher LSD multiple comparisons test was used for comparison of percent injected dose per gram of tissue from each
organ among diﬀerent sample groups for the tissue distribution analysis. A P value ≤ 0.05 was considered to be
statistically signiﬁcant.

3.1. Biodistribution Studies in Normal and S. aureus-Infected
Mice. We ﬁrst evaluated the kinetics of [18F]TZ4877 in mice
at 5, 30, and 60 min postinjection (Table 1). The initial tracer
uptake was high in tissues at 5 min; a rapid clearance of
radioactivity was observed in the majority of tested tissues
including the blood, lung, liver, spleen, kidney, muscle,
heart, brain, pancreas, and thymus from 5 min to 60 min.
Tracer uptake gradually accumulated in the small intestine,
suggesting it had hepatobiliary clearance. In general, at
30 min postinjection in normal Balb/c mice, the muscle
had the lowest tracer uptake among the tissues evaluated
with a %ID/g of 1:4 ± 0:18, whereas the mouse liver and
small intestine had the highest tracer uptake level with
%ID/g of 15:27 ± 0:63 and 11:73 ± 0:59. Notably,
[18F]TZ4877 showed a relatively high mouse brain uptake
with %ID/g of 4:15 ± 0:19 at 30 min postinjection, indicating
that [18F]TZ4877 penetrates the blood-brain barrier well.
We next compared the tissue uptake of [18F]TZ4877
between normal and S. aureus-infected mice. Interestingly,
in response to S. aureus infection, an increase uptake of
[18F]TZ4877 in several tissues was observed. After 30 min
postinjection, the uptake of [18F]TZ4877 in serval organs
including the lung, liver, spleen, brain, heart, kidney,
thyroid, pancreas, thymus, and small intestine of infected
mice was higher than that of sham mice (Table 2; ANOVA:
F ð1, 60Þ = 54:6, P < 0:0001). Fisher’s LSD test following
ANOVA showed that the tracer uptake in several tissues
was signiﬁcantly higher in mice with infections including
the liver (P = 0:002; 30.6% of increase), kidney (P = 0:0031;
54.3% of increase), pancreas (P = 0:0027; 74.3% of increase),
thymus (P = 0:0006; 115.3% of increase), and small intestine
(P < 0:0001; 40.0% of increase).
In addition, the S. aureus-induced increase uptake of
[18F]TZ4877 can be blocked by NIBR-0213 pretreatment
and S1PR1-speciﬁc DsiRNA pretreatment. In general,
NIBR-0213 signiﬁcantly reduced the uptake of
[18F]TZ4877 in several organs of the infected mice
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Table 1: Biodistribution (%ID/g, mean ± SEM) of S1PR1-speciﬁc
[18F]TZ4877 in Balb/c mice (n = 4).
5 min

30 min

60 min

Blood

3:78 ± 0:18

2:53 ± 0:08

2:68 ± 0:03

Lung

8:81 ± 0:44

5:8 ± 0:23

5:18 ± 0:08

Liver

20:07 ± 0:17

15:27 ± 0:63

17:29 ± 0:19

Spleen

4:94 ± 0:24

3:28 ± 0:17

2:92 ± 0:01

Kidney

10:47 ± 0:35

7:34 ± 0:45

6:57 ± 0:09

Muscle

1:76 ± 0:37

1:4 ± 0:18

1:53 ± 0:08

Heart

7:26 ± 0:26

4:39 ± 0:24

4:03 ± 0:13

Brain

4:96 ± 0:36

4:15 ± 0:19

3:78 ± 0:09

Pancreas

8:27 ± 0:51

5:42 ± 0:3

4:75 ± 0:19

Thymus

7:48 ± 0:68

5:61 ± 0:39

6:24 ± 0:56

Small intestine

8:06 ± 0:27

11:73 ± 0:59

17:92 ± 1:06

(Table 2; ANOVA between infected vs. infected with NIBR0213: F ð1, 60Þ = 22:7, P < 0:0001). Fisher’s LSD test following ANOVA showed that the uptake of [18F]TZ4877 was signiﬁcantly decreased after NIBR-0213 pretreatment in the
liver (P = 0:0002; 22.5% of decrease), kidney (P = 0:0225;
30.7% of decrease), and small intestine (P = 0:0011; 12.0%
of decrease). Furthermore, similar to the treatment with
S1PR1 antagonist, S1PR1-speciﬁc DsiRNA also signiﬁcantly
reduced the tracer uptake in the liver and small intestine of
the infected mice to the uptake level of [18F]TZ4877 in sham
mice (Table 2; ANOVA between infected vs. infected with
DsiRNA: F ð1, 60Þ = 15:24, P = 0:0002). Fisher’s LSD test
following ANOVA showed that the tracer uptake was significantly restored after DsiRNA treatment in the liver
(P = 0:0035; 15.4% of decrease) and small intestine
(P < 0:0001; 7.8% of decrease).
3.2. MicroPET Studies in Normal and S. aureus-Infected
Mice. In vivo microPET studies were carried out in three
groups of mice, a low-dose inoculation of bacteria (1 × 106
CFU), a high-dose inoculation of bacteria (1 × 108 CFU),
and sterile PBS buﬀer. Similar to biodistribution results, a
systemic increased uptake of [18F]TZ4877 was identiﬁed in
microPET studies. The radiotracer uptake in the liver and
brain, as well as several other tissues, was signiﬁcantly
increased in the infected mice. Interestingly, the uptake of
[18F]TZ4877 in these organs showed a dose-dependent
manner to the S. aureus infection (Figure 1(b), Supplemental
Figures 1 and 3). For example, tissue time-activity curves
showed that the brain uptake in the infected mice was significantly higher than the uptake in sham mice in a dosedependent manner (Figure 1(c); ANOVA test: high vs. low:
Fð1,120Þ = 9:62, P = 0:0024; high vs. sham: Fð1, 80Þ = 95:6,
P < 0:001; low vs. sham: Fð1,120Þ = 337:2, P < 0:001). Comparing with sham mice, though the diﬀerence between high
and low dose of infection was not statistically diﬀerent, the
uptake of [18F]TZ4877 in infected mice from 30 to 50 min
of the scan was ~49.4% higher in the high-dose group and
~34.8% higher in the low-dose group (Figure 1(d)).

MicroPET study showed that the uptake of [18F]TZ4877
in the hind limb muscle was relatively low with an SUV of
~1.5 in sham mice. Interestingly, though the uptake of
[18F]TZ4877 was low, compared with sham mice, the uptake
of [18F]TZ4877 in the hind limb of S. aureus-infected mice
was signiﬁcantly higher than that of the sham mice. The
average tracer uptake in the hind limb muscle from 30 to
50 min of the PET scan showed a ~39% increase uptake
(SUV) of [18F]TZ4877 in infected mice compared to that
in the normal control mice with a P value of 0.0083
(Figures 2(a)–2(c)). Notably, the increase of tracer uptake
in the muscle was higher than the increase in the brain
and liver of the infected mice (Table 3). Moreover, the
increase of [18F]TZ4877 uptake was only identiﬁed in the
ipsilateral side of the infection site but not in the contralateral site (Supplemental Figures 2 and 3). In contrast, after
24 hours of inoculation, the expression of S1PR1 measured
by PET with [18F]TZ4877 showed almost no uptake in the
hind limb muscle of the high-dose inoculation group
(Supplemental Figure 1).
3.3. Immunohistochemistry Analysis in S. aureus-Infected
Mice. Immunohistochemistry analysis was carried out in
the hind limb muscle of mice with and without infection.
After 24 hours of S. aureus infection, the expression level
of S1PR1 was signiﬁcantly elevated in the muscle of infected
mice in agreement with the increased uptake of [18F]TZ4877
(Figure 3), indicating that the upregulation of S1PR1 was
tightly correlated with the pathogen-derived inﬂammation.

4. Discussion
Increasing evidence indicates that S1PR1 expression is
tightly correlated with the inﬂammatory response to infectious diseases such as viral infections [44–49], bacterial
infections [50–55], protozoan infection [56], and fungal
infection [57, 58]. It is believed that S1PR1 plays an important role in maintaining endothelial barrier function and
integrity in normal as well as inﬂammatory conditions and
can modulate the endothelium to suppress inﬂammatory
responses [59].
Mouse models for infectious diseases caused by S. aureus
have been widely used for the evaluation of S. aureus skin
and soft tissue infection, bacteremia, sepsis, peritonitis, and
endocarditis [3]. Immune-competent mice, such as
C57/BL6 and Balb/c mice, are considered a good candidate
for the study of S. aureus infection in soft tissue [3]. The primary aim of this study was to evaluate if there is a change of
S1PR1 expression in response to S. aureus infection and if
such infection-induced changes of S1PR1 can be detected
by our S1PR1-speciﬁc radiotracer [18F]TZ4877. Therefore,
a relatively high dose of S. aureus, 1 × 106 CFU, was used
to induce the infection, and an even higher dose at 1 × 108
CFU was used to compare if the changes of S1PR1 were S.
aureus dose dependent. In the meantime, in order to detect
the local and systemic changes of S1PR1, a relatively long
inoculation period of 24 hours was chosen. In fact, it has
been well known that soft tissue infection with 10 [7] to 10
[9] CFU S. aureus can cause bacteria to elicit inﬂammatory
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Table 2: Biodistribution of S1PR1-speciﬁc [18F]TZ4877 in sham, infected, and infected with treatments mice (n = 4).

Blood

Sham

Infected

NIBR0213

siRNA

2:33 ± 0:17

1:96 ± 0:81

2:60 ± 0:1

2:46 ± 0:12

5:67 ± 0:22

5:57 ± 0:22

Lung

5:56 ± 0:18

6:68 ± 0:47

Liver

13.52 ± 1.29

17:65 ± 0:16∗∗

Spleen

2:39 ± 0:17

3:48 ± 0:19

3:17 ± 0:12

3:03 ± 0:11

Brain

3:36 ± 0:27

5:24 ± 0:12

4:55 ± 0:17

4:28 ± 0:13

Heart

3:56 ± 0:37

4:84 ± 0:16

4:20 ± 0:14

4:09 ± 0:19

Kidney

5:83 ± 0:39

∗

8:99 ± 0:32

#

7:31 ± 0:18

6:61 ± 0:27

Thyroid

2:83 ± 0:15

4:00 ± 0:12

3:29 ± 0:09

3:20 ± 0:25

4:33 ± 0:34

∗

6:10 ± 0:5

5:83 ± 0:85

Pancreas

14:42 ± 0:46

13:6 ± 0:21##

###

7:55 ± 0:54

∗

Thymus

3:23 ± 0:18

6:94 ± 1:02

5:79 ± 0:76

5:94 ± 0:64

Small intestine

14:96 ± 1:12

20:94 ± 1:60∗∗∗∗

16:31 ± 2:13##

17:48 ± 1:73###

Data represents %ID/g and mean ± SEM, samples with a statistical diﬀerence were in italic; ∗ Fisher’s LSD multiple comparisons between sham and infected
mice: ∗ P < 0:05, ∗∗ P < 0:01, and ∗∗∗∗ P < 0:0001; #Fisher’s LSD multiple comparisons between infected and infected with NIBR0213 or infected and infected
with siRNA: #P < 0:05, ##P < 0:01, and ###P < 0:001.
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Figure 2: MicroPET imaging of S1PR1 activity in S aureus-infected mice. (a) Representative sagittal microPET images of [18F]TZ4877 in the
hind limb of mice. The tracer uptake was relatively low in the hind limb muscle with a SUV of ~1.5 in sham mice. Comparing with sham
mice, the tracer uptake was signiﬁcantly higher in the hind limb of infected mice; (b) time-activity curves showed that the tracer uptake in
infected mice was signiﬁcantly higher than sham mice; (c) the average tracer uptake in the hind limb muscle from 30 to 50 min of the PET
scan showed a ~39% increase of SUV in infected mice with a P value of 0.0082. Data represent the mean ± SEM, n = 3 for each group.

responses within 24 hours [39, 40]; the abscess lesions can
increase over 5 to 7 days after infection [40] and can be gradually revolved over 7 to 9 days [39, 60].
In this study, we report a change of S1PR1 expression
in response to the local S. aureus after 24 hours of infection. We observed a local change of [18F]TZ4877 uptake
at the bacterial infection site as well as increased uptake
of [18F]TZ4877 throughout the body. In general, both
biodistribution and microPET studies showed that
[18F]TZ4877 had high uptake in the majority of tested

organs indicating that PET [18F]TZ4877could be a reliable
tool for quantifying S1PR1 in vivo. For example, at 30 min
postradiotracer injection, the biodistribution data showed
that the liver uptake was ~15.27 (%ID/g); microPET
studies showed that the liver uptake was ~11.40 (SUV).
Notably, [18F]TZ4877 entered the brain well with an
SUV value of ~3.57 at 30 min posttracer injection, indicating that the tracer can penetrate the blood-brain barrier
well and has a great potential for imaging S1PR1 in the
central nervous system.
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Table 3: PET measurements of S1PR1-speciﬁc [18F]TZ4877 in S aureus-infected and sham mice.

Hind limb muscle

Infected∗

Sham∗

P value#

Changes (%)

2:11 ± 0:04

1:52 ± 0:07

=0.0001

38.8%

Brain

3:57 ± 0:12

2:65 ± 0:14

=0.0082

34.8%

Liver

11:40 ± 0:20

10:13 ± 0:12

<0.0001

12.5%

∗

N = 3 per group, mean ± SEM of average SUV from 30 to 50 min. #Two-tailed paired t-test.

Sham

Infected

Figure 3: Immunohistochemistry analysis of S1PR1 in hind limb
muscle of sham and S aureus-infected mice. S1PR1 was
signiﬁcantly upregulated in the muscle of infected mice (red arrow)
comparing with sham mice (green arrow), scale bar = 100 μm.

One of the major ﬁndings of this study is the upregulation of S1PR1 measured by [18F]TZ4877 throughout the
body in response to infection. Remarkably, this infectioninduced upregulation of S1PR1 showed an S. aureus dosedependent manner. S1PR1 is an immune modulator and
plays a crucial role in the regulation of cytokine during
inﬂammation [59]. It is reported that S1PR1 regulates cytokine production and host innate immune responses to pathogen infection [24]. In fact, several studies demonstrated
that S1PR1-speciﬁc ligands can downregulate and control
the massive innate inﬂammatory response, and endogenous
S1P-S1PR1 axis could be a negative regulator of cytokine
production [25, 59, 61]. The mechanisms of S1PR1 in the
regulation of immune responses in response to pathogen
infection remain not clear; our microPET study demonstrates a systemic activation of S1PR1 in response to local
S. aureus infection and provides an evidence of the role of
S1PR1 in the innate inﬂammatory response. In agreement
with our microPET study, biodistribution data also showed
a statistically increased uptake of [18F]TZ4877 in liver,
kidney, and other tissues. In fact, accumulated evidence
suggests that S1PR1 activation and signaling are impaired
during infectious disease. For example, previous studies
report that inﬂuenza infection can alter the expression level
of S1PR1 in the liver, spleen, kidney, and even heart [26].
Also, suppression of early innate immune responses through
S1PR1 signaling can signiﬁcantly reduce mortality during
infection with inﬂuenza virus by suppressing the pathogeninduced excessive host immune response, in other words,
“cytokine storm” [59, 62, 63]. Innate immune response plays
as the ﬁrst line of defense against infections. It is well known
that S1P/S1PR pathways have modulatory eﬀects in cytokine

secretion of innate immune response. In particular, S1PR1
regulates cytokine secretion in various types of cells including dendritic cells, macrophages, T lymphocytes, epithelial
cells, and endothelial cells [61]. It is suggested that targeting
on S1P/SPRR may be an eﬀective therapy for such cases
where the host inﬂammatory response is a major component
in the disease process [61]. Particularly, numerous studies
have shown that acute lung injury is a common consequence
of cytokine storm in Middle East respiratory syndrome
(MERS) and SARS, as well as COVID-19. S1PR1 inhibitor analogs, such as AAL-R and RP-002, which have already shown a
protective eﬀect from the pathophysiological response during
inﬂuenza infection, have been suggested as potential immunomodulators to suppress the cytokine storm. Our study identiﬁed a systemic “storm” of S1PR1 activation in the presence of
pathogens; this ﬁnding may provide a new insight into the
relationship between pathogen-induced S1PR1 activation and
cytokine storm. However, it remains unclear whether the
systemic activation of S1PR1 is the direct result of pathogen
infection; further characterization is required to understand
more about this global protein activation.
On the other hand, accumulated evidence also suggests a
potential role of S1P/S1PR pathways in regulating sepsis
[9–11, 23, 64]. It is hypothesized that the S1P/S1PR pathway
impairs antimicrobial defense in the pathogenesis of sepsis.
The major processes of sepsis include immunological stimulation, systemic inﬂammation, and coagulopathy; recent
studies suggest that the S1P/S1PR1 pathway is involved in
the hyperinﬂammatory phase in sepsis and regulates the
excessive release of cytokine; activation of S1PR1 reduces
the severe complications in sepsis [64]. In fact, S. aureus is
a common cause of sepsis normally caused by the bacterial
replication in blood. Intravenous inoculation of 5 × 107 to
5 × 108 CFU S. aureus can cause the animal to develop septic
shock within 48 hours [42]. Though a mouse model for S.
aureus-induced sepsis is usually introduced intravenously
with up to 5 × 108 CFU S. aureus [3], in our case, a relatively
long infection time was used; the infected animal is possibly
septic 24-hour postinoculation particularly in mice with
high-dose infection. Overall, our study provides a direct evidence of S1PR1 activation in response to pathogen infection;
our microPET study demonstrates the feasibility of imaging
the infection-induced activation of S1PR1 using the S1PR1
speciﬁc tracer [18F]TZ4877. Future studies with diﬀerent
doses of S. aureus and diﬀerent infection times are needed
to understand the precise mechanisms of the S. aureus
infection-induced activation of S1PR1.
In addition to the systemic activation of S1PR1, using
microPET study with [18F]TZ4877, we also observed a local
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upregulation of S1PR1 in the muscle of the infection site but
not the contralateral side of the muscle indicating that such
upregulation of S1PR1 is tightly correlated with pathogenderived inﬂammation. In fact, recent data suggest that bacterial infections may aﬀect inﬂammatory processes in the
vascular wall and atherosclerotic plaque progression in
peripheral arteries [65]. S1P-S1PR1 axis is involved in host
protective eﬀects during the inﬂammation by maintaining
vascular integrity [66]. It is believed that activation of
S1PR1 in endothelial cells can maintain vascular integrity
and prevent vascular leak during inﬂammatory response.
In our case, the local upregulation of S1PR1 in an infected
region could be related to the infection-triggered vascular
leak and is the part of physiological compensatory response
in the endothelial cells to prevent vascular leak during the
inﬂammation. Moreover, S1P-S1PR1 axis also plays an
important role in the control of skeletal muscle metabolism,
atrophy, and regeneration. Previous studies reported that
S1P-S1PR1 axis is involved in the migration of satellite cell
in the injured local to improve skeletal muscle tissue repair
and regeneration [67]; intramuscular S1PR1 is elevated in
regenerating muscle ﬁbers and mediates skeletal muscle
mass and function [68]. The detected upregulation of S1PR1
in the infected region could be related to the changes of muscle
metabolism and regeneration induced by pathogen infection;
further investigation is needed to understand the precise role
of S1PR1 in the muscle in response to pathogen infection.
Although the uptake of [18F]TZ4877 is relatively low in the
muscle, the uptake of [18F]TZ4877 in the muscle of infected
mice was signiﬁcantly higher than that in the muscle of the
control mice. Due to the relatively lower muscle uptake even
in the infected mice, it will be a challenge for PET imaging with
[18F]TZ4877 for the precise assessment of S1PR1 changes in
muscle in response to pathogen infection. However, PET
imaging with [18F]TZ4877 could provide a noninvasive tool
for detecting S1PR1 in response to infection in other organs,
such as the spinal cord, brain, lung, or liver [33, 34].
One limitation of the current study is the use of PBS
instead of heat-killed S. aureus in the contralateral side of
infection as an internal control. Heat-killed S. aureus has
been widely used as an internal control in a murine myositis
model. In this study, we attempt to investigate the S1PR1
expression in response to S. aureus infection using our
S1PR1-speciﬁc radioligand [18F]TZ4877. Previous studies
have demonstrated that heat-killed S. aureus can induce a
strong anti-inﬂammatory response via Toll-Like Receptor 2
(TLR2) pathway; it can induce the production of TNF-α,
IL-6, and IL-10, as well as other cytokines and chemokines
[69–71]. On the other hand, S1P receptors including
S1PR1 can attenuate the TLR2 pathway [72, 73]. To date,
the eﬀect of heat-killed S. aureus on S1PR1 remains unclear.
To minimize the potential eﬀect of heat-killed S. aureus on
S1PR1 expression, we used PBS as an internal control in this
study. Sepsis is a systemic inﬂammatory disease resulting
from pathogen infection and is associated with acute and
chronic changes in the central nervous system, particularly
at the blood-brain barrier (BBB) [74]. To detect the changes
of S1PR1 expression in response to S. aureus infection, an
animal was injected with S. aureus at doses of 1 × 106 CFU
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and 1 × 108 CFU, and a microPET study was performed
post-injection of S. aureus. Although the increased S1PR1
expression at the hind limb of the animal in response to S.
aureus was conﬁrmed by immunohistochemistry study, the
reason that caused the increased brain uptake of
[18F]TZ4877 in response to S. aureus is not clear. The
increased brain uptake of [18F]TZ4877 could be resulted
from increased brain S1PR1 expression or caused by
sepsis-induced BBB breakdown. In addition, the increased
brain uptake of [18F]TZ4877 in response to S. aureus was
based on the assumption that the injection dose of S. aureus
and incubation time (24 hrs) did not cause the sepsis.
Further study using diﬀerent doses of S. aureus and incubation times is necessary to understand the exact mechanisms
of the elevation of S1PR1 in response to S. aureus infection.

5. Conclusions
In summary, we investigated the expression of S1PR1 in S.
aureus-infected mice using both ex vivo biodistribution studies
and microPET imaging; our data suggested that the infectioninduced systemic S1PR1 activation is tightly correlated with
the early immune response to infection. The uptake of the
S1PR1 radiotracer [18F]TZ4877 can be blocked by S1PR1speciﬁc antagonist and S1PR1-speciﬁc DsiRNA. Further
characterization of the mechanisms of infection-induced
systemic S1PR1 activation and translational investigation of
S1PR1 functions in infectious diseases may lead to a new strategy for the diagnosis and the treatment of infectious diseases.

Data Availability
The data that support the ﬁndings of this study are available
from the corresponding author upon request.

Ethical Approval
All animal related experiments were carried out following
the recommendations in the Guide for the Care and Use
of Laboratory Animals of the National Institutes of Health.
All experimental procedures involving animals were
performed according to guidelines established by the
Washington University in St. Louis Institutional Animal
Care and Use Committee (IACUC).

Conflicts of Interest
The authors have no conﬂict of interest to declare.

Acknowledgments
We would like to acknowledge Robert Dennet and
Michael Nickels at Washington University Cyclotron
Facility for Na[18F]/F production. We especially would like
to acknowledge Nicole Fettig, Amanda Klaas, and Lori
Strong at Mallinckrodt Institute of Radiology Preclinical
Imaging Facility for their technical assistance. We thank
Lynne Jones for helpful discussions. This work is supported
by the National Institutes of Health under projects
NS075527, NS103957, NS103988, and EB025815.

Molecular Imaging

9

Supplementary Materials
MicroPET/CT images of S1PR1 activity in sham and S.
aureus-infected mice are provided as supplementary ﬁles.
Supplementary Fig 1: representative sagittal, coronal, and
transverse PET/CT images of [18F]TZ4877 in sham, lowdose infected, and high-dose infected mice. Supplementary
Fig 2: representative PET and PET/CT images of
[18F]TZ4877 in hind limb muscle of sham and S aureusinfected mice. (Supplementary Materials)

[14]

[15]

[16]

References
[1] H. F. Wertheim, D. C. Melles, M. C. Vos et al., “The role of
nasal carriage in _Staphylococcus aureus_ infections,” Lancet
Infect Dis, vol. 5, no. 12, pp. 751–762, 2005.
[2] L. F. McCaig, L. C. McDonald, S. Mandal, and D. Jernigan,
“Staphylococcus aureus-associated skin and soft tissue infections in ambulatory care,” Emerging Infectious Diseases,
vol. 12, no. 11, pp. 1715–1723, 2006.
[3] H. K. Kim, D. Missiakas, and O. Schneewind, “Mouse models
for infectious diseases caused by _Staphylococcus aureus_,”
Journal of immunological methods, vol. 410, pp. 88–99, 2014.
[4] S. Y. C. Tong, J. S. Davis, E. Eichenberger, T. L. Holland,
and V. G. Fowler Jr., “Staphylococcus aureus infections: epidemiology, pathophysiology, clinical manifestations, and
management,” Clinical Microbiology Reviews, vol. 28, no. 3,
pp. 603–661, 2015.
[5] S. Igawa, J. E. Choi, Z. Wang et al., “Human Keratinocytes Use
Sphingosine 1-Phosphate and its Receptors to Communicate
_Staphylococcus aureus_ Invasion and Activate Host
Defense,” Journal of Investigative Dermatology, vol. 139,
no. 8, pp. 1743–1752.e5, 2019.
[6] O. H. Lee, Y. M. Kim, Y. M. Lee et al., “Sphingosine 1phosphate induces angiogenesis: its angiogenic action and signaling mechanism in human umbilical vein endothelial cells,”
Biochem Biophys Res Commun, vol. 264, no. 3, pp. 743–750,
1999.
[7] G. Wang and E. Bieberich, “Sphingolipids in neurodegeneration (with focus on ceramide and S1P),” Advances in biological
regulation, vol. 70, pp. 51–64, 2018.
[8] H. Chi, “Sphingosine-1-phosphate and immune regulation:
traﬃcking and beyond,” Trends Pharmacol Sci, vol. 32, no. 1,
pp. 16–24, 2011.
[9] J. Hou, Q. Chen, K. Zhang et al., “Sphingosine 1-phosphate
receptor 2 signaling suppresses macrophage phagocytosis
and impairs host defense against sepsis,” Anesthesiology,
vol. 123, no. 2, pp. 409–422, 2015.
[10] B. S. Shea and S. M. Opal, “The role of S1PR3 in protection
from bacterial sepsis,” Am J Respir Crit Care Med, vol. 196,
no. 12, pp. 1500–1502, 2017.
[11] A. Feng, A. D. Rice, Y. Zhang, G. T. Kelly, T. Zhou, and
T. Wang, “S1PR1-associated molecular signature predicts survival in patients with sepsis,” Shock, vol. 53, no. 3, pp. 284–292,
2020.
[12] M. Arish, A. Husein, M. Kashif, M. Saleem, Y. Akhter, and
A. Rub, “Sphingosine-1-phosphate signaling: unraveling its
role as a drug target against infectious diseases,” Drug Discovery Today, vol. 21, no. 1, pp. 133–142, 2016.
[13] G. Giovannoni, C. Hawkes, J. Lechner-Scott, M. Levy,
E. Waubant, and J. Gold, “The COVID-19 pandemic and the

[17]

[18]

[19]

[20]

[21]

[22]

[23]

[24]

[25]

[26]

[27]

[28]

use of MS disease-modifying therapies,” Mult Scler Relat Disord, vol. 39, article 102073, 2020.
G. Mallucci, A. Zito, B. D. Fabbro, and R. Bergamaschi,
“Asymptomatic SARS-CoV-2 infection in two patients with
multiple sclerosis treated with ﬁngolimod,” Mult Scler Relat
Disord, vol. 45, article 102414, 2020.
L. Jin, W. R. Liu, M. X. Tian, J. Fan, and Y. H. Shi, “The
SphKs/S1P/S1PR1 axis in immunity and cancer: more ore to
be mined,” World J Surg Oncol, vol. 14, no. 1, p. 131, 2016.
M. Matloubian, C. G. Lo, G. Cinamon et al., “Lymphocyte
egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1,” Nature, vol. 427, no. 6972, pp. 355–
360, 2004.
M. L. Allende, J. L. Dreier, S. Mandala, and R. L. Proia,
“Expression of the Sphingosine 1-Phosphate Receptor, S1P1,
on T-cells Controls Thymic Emigration,” J Biol Chem,
vol. 279, no. 15, pp. 15396–15401, 2004.
L. G. Ledgerwood, G. Lal, N. Zhang et al., “The sphingosine
1-phosphate receptor 1 causes tissue retention by inhibiting
the entry of peripheral tissue T lymphocytes into aﬀerent
lymphatics,” Nature Immunology, vol. 9, no. 1, pp. 42–53,
2008.
M. L. Allende, G. Tuymetova, B. G. Lee, E. Bonifacino, Y. P.
Wu, and R. L. Proia, “S1P1 receptor directs the release of
immature B cells from bone marrow into blood,” The Journal
of experimental medicine, vol. 207, no. 5, pp. 1113–1124, 2010.
M. Ishii, J. G. Egen, F. Klauschen et al., “Sphingosine-1phosphate mobilizes osteoclast precursors and regulates
bone homeostasis,” Nature, vol. 458, no. 7237, pp. 524–
528, 2009.
A. Weigert, B. Weichand, and B. Brune, “S1P regulation of
macrophage functions in the context of cancer,” Anti-cancer
agents in medicinal chemistry, vol. 11, no. 9, pp. 818–829, 2011.
Y. Y. Lan, A. de Creus, B. L. Colvin et al., “The sphingosine-1phosphate receptor agonist FTY720 modulates dendritic cell
traﬃcking in vivo,” American journal of transplantation: oﬃcial journal of the American Society of Transplantation and
the American Society of Transplant Surgeons, vol. 5, no. 11,
pp. 2649–2659, 2005.
Z. Wang, C. R. Sims, N. K. Patil, N. Gokden, and P. R. Mayeux,
“Pharmacologic targeting of sphingosine-1-phosphate receptor 1 improves the renal microcirculation during sepsis in
the mouse,” J Pharmacol Exp Ther, vol. 352, pp. 61–66, 2015.
Y. Li, P. Xie, M. Sun et al., “S1PR1 expression correlates with
inﬂammatory responses to Newcastle disease virus infection,”
Infect Genet Evol, vol. 37, pp. 37–42, 2016.
J. R. Teijaro, K. B. Walsh, J. P. Long et al., “Protection of ferrets
from pulmonary injury due to H1N1 2009 inﬂuenza virus
infection: immunopathology tractable by sphingosine-1phosphate 1 receptor agonist therapy,” Virology, vol. 452453, pp. 152–157, 2014.
S. Tong, J. Tian, H. Wang et al., “H9N2 avian inﬂuenza infection altered expression pattern of sphiogosine-1-phosphate
receptor 1 in BALB/c mice,” Virology journal, vol. 10, p. 296,
2013.
K. Graber, F. Khan, B. Glück et al., “The role of sphingosine-1phosphate signaling in HSV-1-infected human umbilical vein
endothelial cells,” Virus research, vol. 276, article 197835, 2020.
N. I. Lorè, B. Sipione, G. He et al., “Collaborative cross mice
yield genetic modiﬁers for Pseudomonas aeruginosa infection
in human lung disease,” mBio, vol. 11, no. 2, 2020.

10
[29] J. C. Mudd, P. Murphy, M. Manion et al., “Impaired T-cell
responses to sphingosine-1-phosphate in HIV-1 infected
lymph nodes,” Blood, vol. 121, no. 15, pp. 2914–2922, 2013.
[30] F. Naz and M. Arish, “Battling COVID-19 pandemic:
sphingosine-1-phosphate analogs as an adjunctive therapy?,”
Frontiers in Immunology, vol. 11, pp. 1102–1102, 2020.
[31] H. Jin, H. Yang, H. Liu et al., “A promising carbon-11-labeled
sphingosine-1-phosphate receptor 1-speciﬁc PET tracer for
imaging vascular injury,” J Nucl Cardiol, vol. 24, no. 2,
pp. 558–570, 2017.
[32] H. Liu, H. Jin, X. Yue et al., “PET imaging study of S1PR1
expression in a rat model of multiple sclerosis,” Molecular
imaging and biology: MIB: the oﬃcial publication of the Academy of Molecular Imaging, vol. 18, no. 5, pp. 724–732, 2016.
[33] Z. Luo, A. J. Rosenberg, H. Liu, J. Han, and Z. Tu, “Syntheses
and _in vitro_ evaluation of new S1PR1 compounds and initial
evaluation of a lead F-18 radiotracer in rodents,” Eur J Med
Chem, vol. 150, pp. 796–808, 2018.
[34] Z. Luo, J. Han, H. Liu et al., “Syntheses and in vitro biological
evaluation of S1PR1 ligands and PET studies of four F-18
labeled radiotracers in the brain of nonhuman primates,” Org
Biomol Chem, vol. 16, no. 47, pp. 9171–9184, 2018.
[35] H. Liu, Z. Luo, J. Gu et al., “In vivo characterization of four
18F-Labeled S1PR1 tracers for neuroinﬂammation,” Molecular imaging and biology: MIB: the oﬃcial publication of the
Academy of Molecular Imaging, vol. 22, no. 5, pp. 1362–1369,
2020.
[36] M. A. Sellmyer, I. Lee, C. Hou et al., “Bacterial infection imaging with [18F]ﬂuoropropyl-trimethoprim,” Proceedings of the
National Academy of Sciences of the United States of America,
vol. 114, no. 31, pp. 8372–8377, 2017.
[37] G. Gowrishankar, M. Namavari, E. B. Jouannot et al.,
“Investigation of 6-[18F]-ﬂuoromaltose as a novel PET
tracer for imaging bacterial infection,” PLoS One, vol. 9,
no. 9, pp. e107951–e107951, 2014.
[38] E. A. Weinstein, A. A. Ordonez, V. P. DeMarco et al., “Imaging
Enterobacteriaceae
infection
in
vivo
with
18Fﬂuorodeoxysorbitol positron emission tomography,” Sci
Transl Med, vol. 6, no. 259, article 259ra146, 2014.
[39] C. Bunce, L. Wheeler, G. Reed, J. Musser, and N. Barg,
“Murine model of cutaneous infection with gram-positive
cocci,” Infect Immun, vol. 60, no. 7, pp. 2636–2640, 1992.
[40] N. Malachowa, S. D. Kobayashi, K. R. Braughton, and F. R.
DeLeo, “Mouse model of Staphylococcus aureus skin infection,” Methods in molecular biology (Clifton, NJ), vol. 1031,
pp. 109–116, 2013.
[41] M. van Oosten, T. Schäfer, J. A. C. Gazendam et al., “Real-time
_in vivo_ imaging of invasive- and biomaterial-associated bacterial infections using ﬂuorescently labelled vancomycin,”
Nature Communications, vol. 4, no. 1, p. 2584, 2013.
[42] A. G. Cheng, M. McAdow, H. K. Kim, T. Bae, D. M. Missiakas,
and O. Schneewind, “Contribution of coagulases towards
Staphylococcus aureus disease and protective immunity,”
PLoS Pathog, vol. 6, no. 8, article e1001036, 2010.
[43] J. Quancard, B. Bollbuck, P. Janser et al., “A Potent and Selective S1P1 Antagonist with Eﬃcacy in Experimental Autoimmune Encephalomyelitis,” Chemistry & Biology, vol. 19,
no. 9, pp. 1142–1151, 2012.
[44] D. Yamane, M. A. Zahoor, Y. M. Mohamed et al., “Inhibition
of Sphingosine Kinase by Bovine Viral Diarrhea Virus NS3 Is
Crucial for Eﬃcient Viral Replication and Cytopathogenesis,”

Molecular Imaging

[45]

[46]

[47]

[48]

[49]

[50]

[51]

[52]

[53]

[54]

[55]

[56]

[57]

Journal of Biological Chemistry, vol. 284, no. 20, pp. 13648–
13659, 2009.
Y.-J. Seo, C. J. Pritzl, M. Vijayan et al., “Sphingosine kinase 1
serves as a pro-viral factor by regulating viral RNA synthesis
and nuclear export of viral ribonucleoprotein complex upon
inﬂuenza virus infection,” PLoS One, vol. 8, no. 8, article
e75005, 2013.
N. J. Machesky, G. Zhang, B. Raghavan et al., “Human
Cytomegalovirus Regulates Bioactive Sphingolipids,” Journal
of Biological Chemistry, vol. 283, no. 38, pp. 26148–26160,
2008.
M. Vijayan, Y.-J. Seo, C. J. Pritzl, S. A. Squires, S. Alexander,
and B. Hahm, “Sphingosine kinase 1 regulates measles virus
replication,” Virology, vol. 450-451, pp. 55–63, 2014.
M. M. Monick, K. Cameron, L. S. Powers et al., “Sphingosine
kinase mediates activation of extracellular signal-related
kinase and Akt by respiratory syncytial virus,” American journal of respiratory cell and molecular biology, vol. 30, no. 6,
pp. 844–852, 2004.
J. M. Carr, T. Kua, J. N. Clarke et al., “Reduced sphingosine
kinase 1 activity in dengue virus type-2 infected cells can be
mediated by the 3' untranslated region of dengue virus
type-2 RNA,” J Gen Virol, vol. 94, no. 11, pp. 2437–2448,
2013.
A. L. St John, W. X. G. Ang, M.-N. Huang et al., “S1P-Dependent Traﬃcking of Intracellular _Yersinia pestis_ through
Lymph Nodes Establishes Buboes and Systemic Infection,”
Immunity, vol. 41, no. 3, pp. 440–450, 2014.
A. Oizumi, H. Nakayama, N. Okino et al., “Pseudomonasderived ceramidase induces production of inﬂammatory
mediators from human keratinocytes via sphingosine-1phosphate,” PLoS One, vol. 9, no. 2, article e89402, 2014.
Z. A. Malik, C. R. Thompson, S. Hashimi, B. Porter, S. S. Iyer,
and D. J. Kusner, “Cutting Edge:Mycobacterium tuberculosisBlocks Ca2+Signaling and phagosome maturation in human
macrophages via speciﬁc inhibition of sphingosine kinase,”
The Journal of Immunology, vol. 170, no. 6, pp. 2811–2815,
2003.
H. Prakash, A. Lüth, N. Grinkina et al., “Sphingosine
kinase-1 (SphK-1) regulates Mycobacterium smegmatis
infection in macrophages,” PLoS One, vol. 5, no. 5, article
e10657, 2010.
S. Ochi, M. Oda, H. Matsuda, S. Ikari, and J. Sakurai, “_Clostridium perfringens_ α-Toxin Activates the Sphingomyelin
Metabolism System in Sheep Erythrocytes,” Journal of Biological Chemistry, vol. 279, no. 13, pp. 12181–12189, 2004.
M. Yadav, L. Clark, and J. S. Schorey, “Macrophage’s proinﬂammatory response to a mycobacterial infection is dependent
on sphingosine kinase-mediated activation of phosphatidylinositol phospholipase C, protein kinase C, ERK1/2,
and phosphatidylinositol 3-kinase,” The Journal of Immunology, vol. 176, pp. 5494–5503, 2006.
A. Lepletier, L. de Almeida, L. Santos et al., “Early doublenegative thymocyte export in Trypanosoma cruzi infection is
restricted by sphingosine receptors and associated with human
Chagas disease,” PLoS Neglected Tropical Diseases, vol. 8,
no. 10, article e3203, 2014.
T. McQuiston, C. Luberto, and M. Del Poeta, “Role of host
sphingosine kinase 1 in the lung response against cryptococcosis,” Infection and Immunity, vol. 78, pp. 2342–2352,
2010.

Molecular Imaging
[58] T. McQuiston, C. Luberto, and M. Del Poeta, “Role of
sphingosine-1-phosphate (S1P) and S1P receptor 2 in the
phagocytosis of Cryptococcus neoformans by alveolar macrophages,” Microbiology (Reading), vol. 157, pp. 1416–1427,
2011.
[59] J. R. Teijaro, K. B. Walsh, S. Cahalan et al., “Endothelial cells
are central orchestrators of cytokine ampliﬁcation during
inﬂuenza virus infection,” Cell, vol. 146, no. 6, pp. 980–991,
2011.
[60] A. D. Kennedy, J. B. Wardenburg, D. J. Gardner et al., “Targeting of alpha-hemolysin by active or passive immunization
decreases severity of USA300 skin infection in a mouse
model,” The Journal of infectious diseases, vol. 202, no. 7,
pp. 1050–1058, 2010.
[61] K. B. Walsh, J. R. Teijaro, H. Rosen, and M. B. A. Oldstone,
“Quelling the storm: utilization of sphingosine-1-phosphate
receptor signaling to ameliorate inﬂuenza virus-induced cytokine storm,” Immunol Res, vol. 51, no. 1, pp. 15–25, 2011.
[62] D. Marsolais, B. Hahm, K. H. Edelmann et al., “Local not systemic modulation of dendritic cell S1P receptors in lung blunts
virus-speciﬁc immune responses to inﬂuenza,” Mol Pharmacol, vol. 74, no. 3, pp. 896–903, 2008.
[63] D. Marsolais, B. Hahm, K. B. Walsh et al., “A critical role for
the sphingosine analog AAL-R in dampening the cytokine
response during inﬂuenza virus infection,” Proceedings of the
National Academy of Sciences of the United States of America,
vol. 106, no. 5, pp. 1560–1565, 2009.
[64] M. S. Winkler, A. Nierhaus, M. Holzmann et al., “Decreased
serum concentrations of sphingosine-1-phosphate in sepsis,”
Critical Care, vol. 19, no. 1, pp. 372–372, 2015.
[65] J. Budzyński, J. Wiśniewska, M. Ciecierski, and A. Kędzia,
“Association between bacterial infection and peripheral vascular disease: a review,” Int J Angiol, vol. 25, no. 1, pp. 3–13, 2016.
[66] E. Camerer, J. B. Regard, I. Cornelissen et al., “Sphingosine-1phosphate in the plasma compartment regulates basal and
inﬂammation-induced vascular leak in mice,” The Journal of
clinical investigation, vol. 119, pp. 1871–1879, 2009.
[67] M. Fortier, N. Figeac, R. B. White, P. Knopp, and P. S. Zammit,
“Sphingosine-1-phosphate receptor 3 inﬂuences cell cycle progression in muscle satellite cells,” Developmental biology,
vol. 382, no. 2, pp. 504–516, 2013.
[68] N. Ieronimakis, M. Pantoja, A. L. Hays et al., “Increased
sphingosine-1-phosphate improves muscle regeneration in
acutely injured mdx mice,” Skeletal Muscle, vol. 3, p. 20, 2013.
[69] O. M. Peck, D. L. Williams, K. F. Breuel et al., “Diﬀerential regulation of cytokine and chemokine production in
lipopolysaccharide-induced tolerance and priming,” Cytokine,
vol. 26, pp. 202–208, 2004.
[70] O. Takeuchi, K. Hoshino, and S. Akira, “Cutting edge: TLR2deﬁcient and MyD88-deﬁcient mice are highly susceptible to
<em>Staphylococcus aureus</em> infection,” The Journal of
Immunology, vol. 165, pp. 5392–5396, 2000.
[71] A. Lembo, C. Kalis, C. J. Kirschning et al., “Diﬀerential contribution of Toll-like receptors 4 and 2 to the cytokine response
toSalmonella entericaSerovar Typhimurium andStaphylococcus aureusin mice,” Infection and Immunity, vol. 71, no. 10,
pp. 6058–6062, 2003.
[72] A. I. Duenas, M. Aceves, I. Fernandez-Pisonero et al., “Selective attenuation of Toll-like receptor 2 signalling may explain
the atheroprotective eﬀect of sphingosine 1-phosphate,” Cardiovascular Research, vol. 79, no. 3, pp. 537–544, 2008.

11
[73] S. Hamidi, M. Schäfer-Korting, and G. Weindl, “TLR2/1 and
sphingosine 1-phosphate modulate inﬂammation, myoﬁbroblast diﬀerentiation and cell migration in ﬁbroblasts,” Biochim
Biophys Acta, vol. 1841, pp. 484–494, 2014.
[74] T. Barichello, J. S. Generoso, A. Collodel, F. Petronilho, and
F. Dal-Pizzol, “The blood-brain barrier dysfunction in sepsis,”
Tissue Barriers, vol. 9, no. 1, article 1840912, 2021.

